The Clinical Services Journal examines a new collaboration between the Government and the Life Sciences Industry, which aims to save tens of thousands of lives through pioneering research to detect deadly diseases before symptoms appear.
Global biopharmaceutical company UCB is investing £1 billion in research and development, including a new state-of-the-art facility, continuing the UK’s reputation as a world leading base for global life sciences research and industry
The programme, backed by up to £79 million of Government funding, will study 5 m healthy people in a bid to develop new diagnostic tests using Artificial Intelligence (AI). The project is part of the Government’s Life Science’s Sector Deal.
The deal, which brings together 10 companies - and is backed by wide range of organisations from across the sector includes more than £1.3 bn of investment between the public and private sectors. The aim is to ensure that the UK remains in pole position in the treatments, while creating the industries and treatments of the future, such as genomics and AI-powered diagnosis.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
